Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for managing type 2 diabetes mellitus, though certain formulations are now licensed for weight management in adults with obesity or overweight with comorbidities
Shed been on it for two years
Children with rare mutations in the CBS or MTR genes can have neural tube defects, early atherosclerosis, or neurological effects.[ref] Related article : MTHFR and the methylation cycle Sex, age, and smoking: Men tend to have higher homocysteine levels than women, and homocysteine levels in both sexes tend to increase slightly with age
Clinical Studies 14.1 Glycemic Control in Adults with Type 2 Diabetes Mellitus Overview of Clinical Trials of FARXIGA in Adults with Type 2 Diabetes Mellitus FARXIGA has been studied in adult patients as monotherapy, in combination with metformin, pioglitazone, sulfonylurea (glimepiride), sitagliptin (with or without metformin), metformin plus a sulfonylurea, or insulin (with or without other oral antidiabetic therapy), compared to a sulfonylurea (glipizide), and in combination with a GLP-1 receptor agonist (exenatide extended release) added on to metformin
It also slows how quickly the stomach empties, so the feeling of being full lasts longer after a meal
